Print

HVTN 111

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA and of MF59-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants

Trial Details:

I Ongoing
National Institute of Allergy and Infectious Diseases (NIAID) May 01, 2016
DNA-HIV-PT123,Protein/MF59 vaccine DNA clade C ZM96 gag, 2) clade C ZM96 gp140, and 3) clade C CN54 pol-nef; Protein clade C TV1.C gp120 Env and clade C 1086.C gp120 Env
DNA-HIV-PT123 DNA
Protein/MF59 vaccine Protein
MF59
Zambia, Tanzania, South Africa 132
NCT02997969
https://www.clinicaltrials.gov/ct2/show/NCT02997969